There are 2 database that was used in the work. The first database cannot be shared publicly because of National Health Insurance Research Database (NHIRD), Taiwan. This data are available from the NHIRD (<nhird@nhri.org.tw>) for researchers who meet the criteria for access to confidential data. The second database contains single-institute data of TSGH and are within the manuscript and its Supporting Information files.

Introduction {#sec005}
============

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that are naturally responsible for overproducing monoclonal antibodies \[[@pone.0222522.ref001], [@pone.0222522.ref002]\]. The cohort study of Huang \[[@pone.0222522.ref003]\] was the first report to comprehensively describe the epidemiology of MM in Chinese populations. Huang reported that the average incidence and mortality per 100,000 people were 0.75 and 0.59 from 1979 to 2003 \[[@pone.0222522.ref003]\]. In our previous study from 1997 to 2013, the average incidence per 100,000 people was 1.83, which is consistent with recent reports that indicated an increase in the incidence of MM in some Asian countries \[[@pone.0222522.ref003], [@pone.0222522.ref004]\]. Furthermore, the mortality decreased, accounting for an average of 0.44 per 100,000 deaths. Novel agents such as bortezomib and thalidomide were introduced to treat MM \[[@pone.0222522.ref005]\]. Prolonged progression-free survival (PFS) and overall survival (OS) were seen following the National Health Insurance (NHI) Bureau's support of thalidomide from 2009 and bortezomib from 2012 \[[@pone.0222522.ref006]\] and also as a result of advanced supportive care in recent years \[[@pone.0222522.ref007]\].

The Taiwanese NHI system, launched in 1995, currently covers 99% of the population of 23 million people \[[@pone.0222522.ref008]\]. In 1998, the NHI covered nearly 99% of the Taiwanese population. From 1997 to 2013, the NHI program inpatients comprised more than 15 million people. This nationwide database from Taiwan provides an opportunity to evaluate the epidemiology and survival outcomes of numerous patients with MM \[[@pone.0222522.ref009]\].

The use of the novel agent bortezomib was supported from 2012 by the Bureau of the NHI \[[@pone.0222522.ref009]\]. In this retrospective cohort study based in Taiwan, we report the current epidemiology of patients with MM and analyze the first-line versus the non-first-line effect of bortezomib-based therapy on the clinical outcomes of Taiwanese patients with MM. In addition, a single-institute analysis of patients with MM with first-line or non-first-line exposure to bortezomib-based therapy was conducted (Tri-Service General Hospital, TSGH).

Materials and methods {#sec006}
=====================

Data sources and study population {#sec007}
---------------------------------

The National Health Research Institutes, under strict guidelines, makes all confidential patient data from the National Health Insurance Research Database (NHIRD) available in an electronic format for research purposes \[[@pone.0222522.ref004], [@pone.0222522.ref008], [@pone.0222522.ref010]\]. We recovered two data files: the NHIRD and the Longitudinal Health Insurance Database with all inpatient and outpatient records for cancer care \[[@pone.0222522.ref011]\]. We applied the codes of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) to recover diagnosis information.

Ethical considerations {#sec008}
----------------------

The NHIRD provides encrypted personal patient information to maintain privacy and provides researchers with anonymous identification numbers associated with relevant claim information, including the patients' sex, dates of birth, medical services utilized, and prescriptions. Patient consent is not required for access to the NHIRD. The Institutional Review Board (IRB) of the TSGH approved this study (IRB No. 2-102-05-107). Our IRB specifically waived the consent requirement.

Study participants in the NHIRD {#sec009}
-------------------------------

Patient information for this study was provided by the NHIRD and required insurance approval; it included inpatient and outpatient cases. We identified 5,726 patients newly diagnosed with MM (ICD-9 code 203.0) from 2007 to 2015 as the MM cohort. The date of MM diagnosis was established as the index date for starting the measurement of follow-up person-years. All patients were followed up until death, censored for loss to follow-up, withdrawal from the insurance system, or until the end of 2015.

Study participants in a single institute {#sec010}
----------------------------------------

A multiple clinical case study of patients newly diagnosed MM with exposure to bortezomib-based therapy was conducted. At the TSGH, 96 patients with an initial diagnosis of MM were enrolled between January 1, 2002, and December 31, 2018. Because the patients' records/information were anonymized and deidentified prior to analysis in this study, informed consent was not required. The study was performed under the guidelines of the Helsinki Declaration and approved by the Human Subjects Protection Offices (IRB) of the TSGH, National Defense Medical Center, Taiwan. All patients had symptomatic MM in accordance with the diagnostic criteria of the International Myeloma Working Group (IMWG) \[[@pone.0222522.ref012]\]. The clinical information collected from the medical records included age, gender, disease stage at diagnosis, type of myeloma, treatment regimen, hematopoietic stem cell transplantation (HSCT), follow‑up duration, progression-free duration, survival status, and cause of death. The MM stage at diagnosis was in accordance with the International Staging System (ISS) \[[@pone.0222522.ref013]\]. Response to therapy and disease progression was defined according to the IMWG uniform response criteria \[[@pone.0222522.ref012]\].

Statistical analysis {#sec011}
--------------------

In the NHIRD analysis, the distributions of definite sociodemographic factors, including mortality in four-year tracking (with, without), gender (male, female), age, and autologous HSCT (with, without), were displayed in patients with MM undergoing bortezomib-based treatment. The study population was divided into two subgroups: the first was first-line use of bortezomib (the study group) and the other was non-first-line use (the comparison group). We calculated the hazard ratios (HRs) and the 95% confidence interval (CI) using the Cox proportional hazards model to assess the HR of the mortality risk in patients with MM. The multivariate Cox proportional hazards model was used to measure the mortality-association risk factors in patients with MM after adjustment for the timing of bortezomib treatment and sociodemographic characteristics. SAS version 9.1 (SAS Institute, Cary, NC, USA) was used for data analyzes; *p*\<0.05 indicated statistical significance.

In the single-institute study, the OS and PFS were estimated using the Kaplan--Meier (KM) method and the difference in survival between the subgroups was compared using the log-rank test. In order to investigate the associated factors of the OS and PFS, univariate and multivariate Cox proportional hazard regressions were performed. The results are presented as HRs and their corresponding 95% CIs. In the subgroup analysis, the patients' characteristics were compared as in the NHIRD subgroup design (first-line use of bortezomib versus non-first-line use of bortezomib) using the chi-squared test. All data analyzes were performed using SPSS software version 25 (SPSS Inc., Chicago, IL, USA).

Results {#sec012}
=======

NHIRD analysis {#sec013}
--------------

[Fig 1](#pone.0222522.g001){ref-type="fig"} shows the flowchart of the study sample selection from the Taiwanese NHIRD. As a result, 5,580 patients with MM were enrolled. Among them, there were 1,116 patients with MM from January 2007 to October 2011 as the comparison cohort and 4,610 patients with MM from November 2011 to December 2015 as the study cohort with a 1 : 4 pairing by gender, age, and so forth. Both cohorts were followed up for four years. [Table 1](#pone.0222522.t001){ref-type="table"} shows the distribution of the basic characteristics of the patients with MM. There were no significant differences between the groups in terms of gender, age, concomitant diseases, autologous HSCT, and Charlson Comorbidity Index scores, except for mortality in four-year tracking (*p* = 0.001). The KM analysis of cumulative OS in the four-year tracking demonstrated that the study cohort had longer OS compared to the control cohort (p \< 0.001, [Fig 2](#pone.0222522.g002){ref-type="fig"}).

![Flowchart of the study sample selection from the NHIRD in Taiwan.\
MM: ICD-9-CM 203.0. Inclusion criteria: MM. Exclusion criteria: gender unknown.](pone.0222522.g001){#pone.0222522.g001}

![KM test for cumulative OS in four-year tracking among patients with MM aged 18 and above treated with bortezomib (NHIRD analysis).](pone.0222522.g002){#pone.0222522.g002}

10.1371/journal.pone.0222522.t001

###### Characteristics of patients with MM treated with bortezomib in the NHIRD analysis.

![](pone.0222522.t001){#pone.0222522.t001g}

  Bortezomib                            Total           First-line      Non-first-line   P                       
  ------------------------------------- --------------- --------------- ---------------- ------- ------- ------- --------------------------------------------
  **Total**                             5,580                           4,464            80.00   1,116   20.00   
  **Mortality in four-year tracking**                                                                            0.001[\*](#t001fn004){ref-type="table-fn"}
  Without                               4,657           83.46           3,762            84.27   895     80.20   
  With                                  923             16.54           702              15.73   221     19.80   
  **Gender**                                                                                                     0.999
  Male                                  3,370           60.39           2,696            60.39   674     60.39   
  Female                                2,210           39.61           1,768            39.61   442     39.61   
  **Age (years)**                       66.36 ± 12.65   66.20 ± 12.46   67.01 ± 13.35    0.056                   
  **DM**                                                                                                         0.518
  Without                               4,975           89.16           3,974            89.02   1,001   89.70   
  With                                  605             10.84           490              10.98   115     10.30   
  **HTN**                                                                                                        0.953
  Without                               4,837           86.68           3,869            86.67   968     86.74   
  With                                  743             13.32           595              13.33   148     13.26   
  **COPD**                                                                                                       0.828
  Without                               5,308           95.13           4,245            95.09   1,063   95.25   
  With                                  272             4.87            219              4.91    53      4.75    
  **CAD**                                                                                                        0.559
  Without                               4,650           83.33           3,713            83.18   937     83.96   
  With                                  930             16.67           751              16.82   179     16.04   
  **Stroke**                                                                                                     0.604
  Without                               5,363           96.11           4,287            96.03   1,076   96.42   
  With                                  217             3.89            177              3.97    40      3.58    
  **CCI_R**                             0.68 ± 1.01     0.69 ± 1.01     0.65 ± 0.99      0.228                   
  **BMT**                                                                                                        0.209
  Without                               4,712           84.44           3,756            84.14   956     85.66   
  With                                  868             15.56           708              15.86   160     14.34   

P-value (categorical variables: chi-squared/Fisher's exact test; continuous variables: *t*-test).

CCI_R: Charlson Comorbidity Index excluding cancer.

DM: diabetes mellitus; HTN: hypertension; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; MM: multiple myeloma; BMT: bone marrow autotransplantation.

\*P \< 0.05

The single-variable and multivariable analyses of the mortality risk factors are shown in [Table 2](#pone.0222522.t002){ref-type="table"}. Non-first-line use of bortezomib, male gender, and older age were the significant factors for increased myeloma death in the four-year tracking. The influence of the Charlson Comorbidity Index_R (CCI_R) score and patients with/without autologous HSCT were only statistically important in the multivariable analysis (adjusted HR: 1.075, *p* = 0.03; adjusted HR: 0.73, *p* = 0.04, respectively). Furthermore, the importance of autologous HSCT in different subgroups was analyzed and is shown in [Fig 3](#pone.0222522.g003){ref-type="fig"}. Patients who received first-line bortezomib-containing regimens followed by autologous HSCT had better survival benefit compared to the other groups (adjusted HR: 0.39, *p*\<0.001).

![Factors of mortality in four-year tracking among patients with MM stratified by bortezomib treatment and BMT (NHIRD analysis).](pone.0222522.g003){#pone.0222522.g003}

10.1371/journal.pone.0222522.t002

###### Mortality factors in four-year tracking among patients with MM treated with bortezomib using Cox regression (NHIRD analysis).

![](pone.0222522.t002){#pone.0222522.t002g}

  Variables         Crude HR    95% CI   95% CI   P                                                  Adjusted HR   95% CI   95% CI   P
  ----------------- ----------- -------- -------- -------------------------------------------------- ------------- -------- -------- --------------------------------------------------
  **Bortezomib**                                                                                                                     
  First-line        0.709       0.609    0.825    \<0.001[\*\*\*](#t002fn008){ref-type="table-fn"}   **0.683**     0.586    0.795    \<0.001[\*\*\*](#t002fn008){ref-type="table-fn"}
  Non-first-line    Reference                                                                        Reference                       
  **Gender**                                                                                                                         
  Male              1.292       1.129    1.478    \<0.001[\*\*\*](#t002fn008){ref-type="table-fn"}   **1.292**     1.128    1.479    \<0.001[\*\*\*](#t002fn008){ref-type="table-fn"}
  Female            Reference                                                                        Reference                       
  **Age (years)**   1.013       1.008    1.019    \<0.001[\*\*\*](#t002fn008){ref-type="table-fn"}   **1.017**     1.011    1.023    \<0.001[\*\*\*](#t002fn008){ref-type="table-fn"}
  **DM**                                                                                                                             
  Without           Reference                                                                        Reference                       
  With              1.146       0.919    1.429    0.228                                              1.153         0.915    1.454    0.228
  **HTN**                                                                                                                            
  Without           Reference                                                                        Reference                       
  With              1.368       1.107    1.692    0.004[\*\*](#t002fn007){ref-type="table-fn"}       1.078         0.710    1.637    0.724
  **COPD**                                                                                                                           
  Without           Reference                                                                        Reference                       
  With              0.977       0.719    1.326    0.879                                              1.172         0.855    1.606    0.324
  **CAD**                                                                                                                            
  Without           Reference                                                                        Reference                       
  With              1.351       1.118    1.683    0.002[\*\*](#t002fn007){ref-type="table-fn"}       1.355         0.934    1.965    0.110
  **Stroke**                                                                                                                         
  Without           Reference                                                                        Reference                       
  With              0.987       0.710    1.371    0.936                                              1.152         0.823    1.612    0.410
  **CCI_R**         1.055       0.991    1.123    0.092                                              **1.075**     1.006    1.149    0.033[\*](#t002fn006){ref-type="table-fn"}
  **BMT**                                                                                                                            
  Without           Reference                                                                        Reference                       
  With              0.892       0.507    1.063    0.094                                              **0.725**     0.456    0.990    0.040[\*](#t002fn006){ref-type="table-fn"}

P-value (categorical variables: chi-squared/Fisher's exact test; continuous variables: *t*-test).

CCI_R = Charlson Comorbidity Index removed cancer

Crude HR: crude hazard ratio; CI: confidence interval; adjusted HR: adjusted variables listed in the table.

DM: diabetes mellitus; HTN: hypertension; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; BMT: bone marrow autotransplantation; MM: multiple myeloma

Nagelkerke's R-square of the model = 0.138.

\* P \< 0.05

\*\* P \< 0.01

\*\*\* P \< 0.001.

Single-institute analysis {#sec014}
-------------------------

In addition to the nationwide population‑based cohort study, a single‑institute analysis of patients with MM and bortezomib-based therapy was performed. The patients' profiles are described in [Table 3](#pone.0222522.t003){ref-type="table"}. The 96 patients with MM treated with bortezomib-based therapy comprised 51 males (51.7%) and 45 females (48.3%), with a median age of 68.7 ± 12 years. There were 13 patients with stage 1 disease (5.2%), 36 patients with stage 2 disease (34.5%), and 47 patients with stage 3 disease (60.3%). 44 patients were diagnosed with IgG-type myeloma (45.8%), 29 with light-chain-type myeloma (30.2%), 21 with IgA-type myeloma (21.9%), and 2 with nonsecretory-type myeloma (2.1%).

10.1371/journal.pone.0222522.t003

###### Characteristics of patients with MM treated with bortezomib at a single institute (TSGH).

![](pone.0222522.t003){#pone.0222522.t003g}

  Bortezomib                       Total       First-line    Non-first-line   P                          
  -------------------------------- ----------- ------------- ---------------- ------- ---- ------------- -------
  **Total**                        96                        58               60.42   38   39.58         
  **Mortality in tracking**                                                                              0.023
  Without                          44          45.83         32               55.17   12   31.58         
  With                             52          54.17         26               44.83   26   68.42         
  OS (months)                                                                 56.4         70.6 ± 11.1   0.76
  **Gender**                                                                                             0.734
  Male                             51          53.13         30               51.72   21   55.26         
  Female                           45          46.88         28               48.28   17   44.74         
  **Age (years)**                  68.7 ± 12   67.5 ± 11.9   67.3 ± 11.2      0.282                      
  **Disease stage at diagnosis**                                                                         0.085
  I                                10          10.42         3                5.17    7    18.42         
  II                               34          35.42         20               34.48   14   36.84         
  III                              52          54.17         35               60.34   17   44.74         
  **Myeloma type**                                                                                       0.093
  IgG                              44          45.83         26               44.83   23   60.53         
  IgA                              21          21.88         13               22.41   6    15.79         
  Light chain                      29          30.21         19               32.76   7    18.42         
  Nonsecretory                     2           2.08          0                0       2    5.26          
  **BMT**                                                                                                0.092
  Without                          72          75            40               68.97   32   84.21         
  With                             24          25            18               31.03   6    15.79         

P-value (categorical variables: chi-squared/Fisher's exact test; continuous variables: *t*-test).

OS: overall survival; BMT: bone marrow autotransplantation; MM: multiple myeloma

Bortezomib-based therapy as the first-line treatment had estimated OS of 56.4 months and PFS of 35 ± 6.5 months. There was no statistical difference in the OS or PFS according to gender, myeloma type, ISS stage, or treatment regimen. However, there was a significant difference in PFS between patients receiving first-line bortezomib with autologous HSCT compared to those receiving first-line bortezomib without HSCT (52.8 ± 8.0 months versus 31.5 ± 7.0 months, P = 0.021) ([Fig 4](#pone.0222522.g004){ref-type="fig"}).

![KM test for PFS of bone marrow transplantation in the first-line bortezomib group (TSGH analysis).](pone.0222522.g004){#pone.0222522.g004}

When first-line bortezomib-based therapy was compared with non-first-line bortezomib therapy, there was no significant difference in the OS (56.4 versus 70.6 months, P = 0.76) ([Fig 5](#pone.0222522.g005){ref-type="fig"}).

![KM test for cumulative OS in the first-line and non-first-line bortezomib group (TSGH analysis).](pone.0222522.g005){#pone.0222522.g005}

Discussion {#sec015}
==========

Bortezomib is an anticancer drug and the first therapeutic proteasome inhibitor to be used in humans \[[@pone.0222522.ref014]\]. Bortezomib interrupts this process and enables normal mechanism to kill cancer cells. In May 2003, seven years after its initial synthesis, bortezomib was approved in the United States by the US Food and Drug Administration (FDA) for use in MM on the basis of the results of the SUMMIT Phase II trial \[[@pone.0222522.ref015]\]. Bortezomib was approved by the US FDA for the initial treatment of patients with MM in 2008 \[[@pone.0222522.ref016]\].

The use of novel agents such as bortezomib was supported as a first-line treatment from 2012 by the Bureau of the NHI, Taiwan, which prolonged the PFS and OS duration. During the past three decades, the incidence of MM has increased significantly in Taiwan. The possible causes may be improved diagnostic techniques, aging of the population, and increased exposure to carcinogens. In previous studies, the introduction of novel agents, such as thalidomide and bortezomib, as a first-line treatment for patients with MM resulted in a 24% decrease in fatality \[[@pone.0222522.ref017]\]. To the best of our knowledge, there is no published literature available that compares the efficacy of first-line to non-first-line bortezomib-based treatment in Taiwan.

In our NHIRD analysis, the risk of hospital death was significantly lower for the study cohort than for the control cohort in the four-year mortality tracking. Regarding the synergism of bortezomib use and autologous HSCT, the results showed that patients with MM receiving first-line bortezomib-based regimen and autologous HSCT treatment were the lowest hospital death risk group and that patients receiving non-first-line bortezomib without bone marrow transplantation were the highest risk group. This was consistent with the real-world experience \[[@pone.0222522.ref018]\]. Patients with MM who receive bone marrow transplantation are under 60 years of age \[[@pone.0222522.ref019]\]. For every one year added to the patient's age, the probability of hospital death increased by 1.7% (p \< 0.001) and the probability of hospital death in men was 1.92 times that in women (p \< 0.001).

In the subgroup ineligible for autologous HSCT, first-line bortezomib treatment did reduce the hospital death risk (the first-line was 0.681 times that of the non-first-line) (p \< 0.001). In the non-first-line bortezomib treatment group, the hospital death risk was 0.724 times that of the nonautologous HSCT group (p = 0.040). Furthermore, the hospital death risk in the first-line bortezomib without HSCT group was similar to that in the non-first-line bortezomib with HSCT group (0.683 versus 0.725). In short, bortezomib as a first-line treatment was important and effective in reducing the hospital death risk for MM.

There were some limitations in the NHIRD analysis. First, the NHIRD did not offer detailed information, such as tumor stage and cause of death, so we could not show stage-stratified survival rates and disease-specific survival rates. Second, we were unable to have direct access to the patients to obtain additional information because of the anonymity ensured by the identification numbers. Third, we could not evaluate certain biological factors, such as genomics, because they were not included in the NHIRD. The staging system for MM includes serum albumin, B2 macroglobulin and cytogenetic profiles, and gene expression profiles. However, these data were limited in the NHIRD. Finally, the results derived from a cohort study are generally of a lower methodological quality than those from randomized trials, because cohort study designs are subject to several biases related to the adjustment for confounders.

In order to overcome the limitations of the NHIRD analysis, a single-institute analysis was conducted for detailed prognostic factors and treatment outcome analysis. In the single-institute analysis, patients who were exposed to first-line bortezomib treatment showed no significant difference in the OS or PFS according to gender, myeloma type, ISS stage, and treatment response. The PFS was only significantly longer in the transplanted group compared to the nontransplanted group. This result means that once bortezomib is administered, patients can achieve a better clinical outcome consistent with previous studies \[[@pone.0222522.ref020]--[@pone.0222522.ref022]\].

The OS was not significantly different when first-line and non-first-line bortezomib were compared. This result was not consistent with the NHIRD analysis result, indicating that there may be some limitations among the enrolled patients. A review of the participants indicated there may be three limitations causing this result. First, the number of enrolled patients was smaller than in the NHIRD analysis (96 versus 5,580). Second, there were six patients with extremely long survival times in the non-first-line group. Third, there were eight patients enrolled in the first-line group who received a relatively short duration (less than three months) of bortezomib treatment. These limitations were mostly accounted for when performing the NHIRD analysis. However, the single-institute analysis still reflected the real-world bortezomib-based treatment experience and allowed more detailed influencing factors, such as myeloma type and response, to be analyzed.

In conclusion, first-line bortezomib-based therapy reduced the hospitalization death risk for Taiwanese patients with MM compared with non-first-line bortezomib-based therapy. Second, first-line bortezomib use in patients with MM who are ineligible for HSCT may have a clinical outcome similar to those eligible for HSCT. Third, the initial patient conditions play a less important role once the patients with MM have received bortezomib therapy.

In the future, we could prospectively collect nationwide data, including detailed information, to provide the most representative data on the bortezomib treatment results for patients with MM in Taiwan. This can not only provide stage-stratified survival and disease-specific survival rates but also help identify better clinical effects.

Supporting information {#sec016}
======================

###### The single-institute data of TSGH.

(XLSX)

###### 

Click here for additional data file.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This retrospective cohort study was designed to evaluate the characteristics, treatment outcome, and prognostic factors of MM patients who received Bortezomib-based therapy. The study was based on the Taiwan National Health Institute Research Database (NHIRD) and the Tri-Service General Hospital (TSGH).

This is an interesting epidemiological study. However, the study is difficult to follow due to poor English language skills.

Reviewer \#2: In this work Liu and colleagues report the epidemiology of MM in Taiwan and analyze the outcome of bortezomib-treated MM patients. The study is based on data of Taiwan National Health Institute Research Database (NHIRD) and completed with a single institutional experience.

The work is well written and rationally conducted. Results are convincing and well discussed. The statistical analysis is rationale and adequate to achieve a correct evaluation of data. The study provide some useful information about epidemiology of MM in Taiwan and about the role of bortezomib therapy for the treatment of MM patients.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Carmelo Carlo-Stella

Reviewer \#2: Yes: Roberto Ria

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

13 Aug 2019

Dear Francesco Bertolini, Editor,

Thank you for inviting us to submit a revised draft of our manuscript entitled, "The clinical outcomes of Bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single institute analysis" to PLOS ONE. We also appreciate the time and effort you and each of the reviewers have dedicated to providing insightful feedback on ways to strengthen our paper. Thus, it is with great pleasure that we resubmit our article for further consideration. We have incorporated changes that reflect the detailed suggestions you have graciously provided. We also hope that our edits and the responses we provide below satisfactorily address all the issues and concerns you and the reviewers have noted.

To facilitate your review of our revisions, the following is a point-by-point response to the questions and comments delivered in your letter dated 31 July 2019.

Journal requirements:

Question 1,

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Answer,

Thank you for providing these insights. We had done our best to complete revision of the manuscript, the language, the reference form, and the terminology.

Question 2,

Thank you for including your ethics statement: \"The NHIRD provides encrypted personal patient information to maintain privacy and provides researchers with anonymous identification numbers associated with relevant claim information, including patients' sex, dates of birth, medical services utilized, and prescriptions. Patients' consent is not required for accessing the NHIRD. The Institutional Review Board of TSGH approved this study. Our IRB specifically waived the consent requirement.\"

a\. Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b\. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

Answer,

Thank you for your comments. The full name of the ethics committee/institutional review board(s) that approved our specific study was described in the new manuscript as "The Institutional Review Board (IRB) of the TSGH approved this study (IRB No. 2-102-05-107)". ( Page 6, Line 4-5) We also added the same text to the "Ethics Statement" field of the submission form.

Question 3,

In the Introduction section, we noticed several occurrences of overlapping text with your following previous publication, which need to be addressed:

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0167227>

In your revision please ensure you quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

Answer,

Thank you for your comments. We had revised the overlapping text with our previous publication carefully. We also ensure to avoid duplicated text outside the methods section in the revision.

Revision in manuscript:

Page 4, Line 11-13

In our previous study from 1997 to 2013, the average incidence per 100,000 people was 1.83, which is consistent with recent reports that indicated an increase in the incidence of MM in some Asian countries.

Page 4, Line 14-15

Furthermore, the mortality decreased, accounting for an average of 0.44 per 100,000 deaths. Novel agents such as bortezomib and thalidomide were introduced to treat MM.

Page 4, Line 16-19

Prolonged progression-free survival (PFS) and overall survival (OS) were seen following the National Health Insurance (NHI) Bureau's support of thalidomide from 2009 and bortezomib from 2012 \[6\] and also as a result of advanced supportive care in recent years.

Page 4, Line 21-22

The Taiwanese NHI system, launched in 1995, currently covers 99% of the population of 23 million people.

Page 5, Line 3-9

The use of the novel agent bortezomib was supported from 2012 by the Bureau of the NHI. In this retrospective cohort study based in Taiwan, we report the current epidemiology of patients with MM and analyze the first-line versus the non-first-line effect of bortezomib-based therapy on the clinical outcomes of Taiwanese patients with MM. In addition, a single-institute analysis of patients with MM with first-line or non-first-line exposure to bortezomib-based therapy was conducted (Tri-Service General Hospital, TSGH).

Question 4,

We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Answer,

Thank you for your comments. We thoroughly copyedit our manuscript for language usage, spelling, and grammar by employing a professional scientific editing service. We also seriously add the certification in the resubmission.

Responses to Reviewer\'s Questions

Reviewer \#1:

Comment: This retrospective cohort study was designed to evaluate the characteristics, treatment outcome, and prognostic factors of MM patients who received Bortezomib-based therapy. The study was based on the Taiwan National Health Institute Research Database (NHIRD) and the Tri-Service General Hospital (TSGH). This is an interesting epidemiological study.

Question: The study is difficult to follow due to poor English language skills.

Response,

Thank you for your important comments. We had seriously and carefully copyedited our manuscript for language usage, spelling, and grammar by employing a professional scientific editing service. Our team will also do our best to improve English language skills to compose better article easy to follow in the future.

Reviewer \#2:

Comment: In this work Liu and colleagues report the epidemiology of MM in Taiwan and analyze the outcome of bortezomib-treated MM patients. The study is based on data of Taiwan National Health Institute Research Database (NHIRD) and completed with a single institutional experience.

The work is well written and rationally conducted. Results are convincing and well discussed. The statistical analysis is rationale and adequate to achieve a correct evaluation of data. The study provide some useful information about epidemiology of MM in Taiwan and about the role of bortezomib therapy for the treatment of MM patients.

Response,

Thank you for your valuable comments. We will do our best to do valuable research in the future.

###### 

Submitted filename: Response_to_Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0222522.r003
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\[EXSCINDED\]

Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis

PONE-D-19-16145R1

Dear Dr. Chen,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Francesco Bertolini, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The paper has been carefully revised according to the reviewer\'s comment with a specific emphasys on English language editing.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Carmelo Carlo-Stella
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PONE-D-19-16145R1

Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis

Dear Dr. Chen:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Francesco Bertolini

Academic Editor

PLOS ONE
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